Axil Capital

Axil Capital

A venture capital and private equity firm investing in early-stage biomedical & healthcare technology companies.

Axil Capital is a venture capital and private equity firm investing in early-stage biomedical & healthcare technology companies that is headquartered in Tokyo, Japan and was founded in 2017 by Fred Shane and Hiroshi Gonaikawa. Axil Capital was spun out of Mizuho Securities in 2017 after receiving investment from the Japanese Government, a global pharmaceutical company, and a few small investors.

Notable investments made by Axil Capital include: Jolly Good! (sereis B-II), Frequency Therapeutics (series B and series C), United Immunity (series A), TechsoMed (series A).

Investment funds

According to the firms website (as of November 2019), Axil Capital has one investment fund called the Axil Life Science & Healthcare Fund No.1 L.P. (ALHF I).

Timeline

Funded Companies

Company
Industry
Website
Location
Frequency Therapeutics
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.